ethris GmbH develops innovative therapeutics based on proprietary platform technologies with high diversification potential that enable therapies for diseases with currently dissatisfying treatment options.
Magnetovax® is a platform for personalized tumor vaccines that are localized and activated specifically in tumors by magnetic fields. SNIM® RNA is a first-in-class biopharmaceutical platform for therapies of rare diseases, replacement of recombinant proteins, and for “Transcript Therapies” in regenerative medicine. ethris enabling therapies provide access to highly profitable markets.
ethris was founded at the end of 2009 by Dr. Carsten Rudolph (CEO) and Dr. Christian Plank (CSO) and was later joined by Dr. Walter Schmidt. The goal of ethris is to rapidly and continuously translate its world-wide unique expertise into clinical trials.
Munich, Germany January 7, 2013. Ethris GmbH and Shire today announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics.
With teir project "SNIM® RNA - a new class of RNA biopharmaceuticals" PD Dr. Carsten Rudolph and Prof. Christian Plank are among the winners of the 4th Selection round of the "Go-Bio" call funded by the Federal Ministry of Education and Research (BMBF).
The life-saving potency of the SNIM® RNA technology platform has been demonstrated in a recent preclinical study in a mouse model of the fatal human hereditary disease surfactant protein B deficiency. The results of the study have been published in Nature Biotechnology on 09 January 2011 (doi:10.1038/nbt.1733).
On 16th September the CVMP at the EMA decided to classify Felovectin as „Product for Minor Use or Minor Species (MUMS)” for the treatment of feline fibrosarcoma and also financial incentives announced will apply for a period of up to five years. This is an important achievement towards the next steps of marketing authorisation application of Felovectin for the treatment of feline fibrosarcoma.
Within the Excellence Stage - Level 3 - of the Munich Business Plan (MBPW) Competion 2010 ethris was nominated for the final round. Therewith ethris accounts to the 9 nominees of in total 57 submitted business plans of level 3 of the competition in 2010.
ethris has been informed about the positive expert opinion on a research grant which has been submitted to the German Federal Ministry of Research and Education (BMBF) within the call "Effizienter Wirkstofftransport in biologischen Systemen - BioMatVital: BioTransporter" of the funding program "Werkstoffinnovationen für Industrie und Gesellschaft - WING".
On 28 January 2010 ethris GmbH has been assigned SME status by the EMA and is now eligible to benift from the provisons for administrative and financial assistance laid down in the Regulation (EC) No 2049/2005.
ethris has been informed about the positive expert opinion on a research grant which has been submitted to the German Federal Ministry of Research and Education (BMBF) within the call "KMU-innovativ: Nanotechnologie (NanoChance)".